Drug lookup | Fillwise

Ach-Apixaban · DIN 02487713 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Apixaban · DIN 02487713 Manufacturer: Accord Healthcare Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-27 · brand ACH-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97786 · Verify on the e-Formulary ↗ (DIN 02487713)

Source record

DIN 02487713: Ach-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id ACH Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487713 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97786

Interchangeable products

Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: resolved shortage (ended 2025-11-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487713

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apixaban · DIN 02530708 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apixaban · DIN 02530708 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-12-21 Health Canada: Marketed since 2026-08-07 · brand APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101986 · Verify on the e-Formulary ↗ (DIN 02530708)

Source record

DIN 02530708: Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530708 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101986

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02530708

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apixaban · DIN 02548879 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apixaban · DIN 02548879 Manufacturer: Sanis Health Inc.; listing date 2024-12-30 Health Canada: Marketed since 2024-11-06 · brand APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103770 · Verify on the e-Formulary ↗ (DIN 02548879)

Source record

DIN 02548879: Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548879 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103770

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: shortage reported ended 2026-08-24 (report last updated 2026-08-24); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02548879

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Apixaban · DIN 02487381 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Apixaban · DIN 02487381 Manufacturer: Apotex Inc.; listing date 2022-08-31 Health Canada: Marketed since 2022-06-20 · brand APO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97756 · Verify on the e-Formulary ↗ (DIN 02487381)

Source record

DIN 02487381: Apo-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487381 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97756

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487381

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Apixaban · DIN 02486806 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Apixaban · DIN 02486806 Manufacturer: Auro Pharma Inc.; listing date 2023-01-31 Health Canada: Marketed since 2022-11-28 · brand AURO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97697 · Verify on the e-Formulary ↗ (DIN 02486806)

Source record

DIN 02486806: Auro-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id AUR Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02486806 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97697

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: resolved shortage (ended 2025-01-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486806

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Apixaban · DIN 02527979 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Bio-Apixaban · DIN 02527979 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2022-09-21 · brand BIO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Biomed pharma · schedule Prescription

Check this DIN again · Health Canada product record

Bio-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101724 · Verify on the e-Formulary ↗ (DIN 02527979)

Source record

DIN 02527979: Bio-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id BMP Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527979 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101724

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527979

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Eliquis · DIN 02377233 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists ELIQUIS (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Eliquis · DIN 02377233 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2013-08-29 Health Canada: Marketed since 2012-02-01 · brand ELIQUIS · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Bristol-myers squibb canada · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86287 · Verify on the e-Formulary ↗ (DIN 02377233)

Source record

DIN 02377233: Eliquis Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id BQU Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.6336; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02377233 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86287

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02377233

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Apixaban · DIN 02528924 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Apixaban · DIN 02528924 Manufacturer: Jamp Pharma Corporation; listing date 2022-11-30 Health Canada: Marketed since 2022-09-20 · brand JAMP APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101810 · Verify on the e-Formulary ↗ (DIN 02528924)

Source record

DIN 02528924: Jamp Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528924 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101810

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528924

Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Apixaban · DIN 02529009 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

M-Apixaban · DIN 02529009 Manufacturer: Mantra Pharma Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-21 · brand M-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Mantra pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

M-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101820 · Verify on the e-Formulary ↗ (DIN 02529009)

Source record

DIN 02529009: M-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id MAT Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529009 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101820

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529009

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Apixaban · DIN 02492369 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Apixaban · DIN 02492369 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-21 · brand MAR-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98239 · Verify on the e-Formulary ↗ (DIN 02492369)

Source record

DIN 02492369: Mar-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id MAR Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492369 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98239

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492369

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Apixaban · DIN 02495430 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Apixaban · DIN 02495430 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2023-07-31 Health Canada: Marketed since 2023-04-17 · brand MINT-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98535 · Verify on the e-Formulary ↗ (DIN 02495430)

Source record

DIN 02495430: Mint-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id MIN Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495430 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98535

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495430

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Apixaban Tablets · DIN 02546884 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Apixaban Tablets · DIN 02546884 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-04-22 · brand NRA-APIXABAN TABLETS · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Apixaban Tablets: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103555 · Verify on the e-Formulary ↗ (DIN 02546884)

Source record

DIN 02546884: NRA-Apixaban Tablets Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id NRA Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546884 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103555

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546884

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Apixaban · DIN 02492814 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Nat-Apixaban · DIN 02492814 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-21 · brand NAT-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Natco pharma (canada) inc · schedule Prescription

Check this DIN again · Health Canada product record

Nat-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98281 · Verify on the e-Formulary ↗ (DIN 02492814)

Source record

DIN 02492814: Nat-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id NAT Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492814 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98281

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02492814

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Apixaban · DIN 02525518 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Riva-Apixaban · DIN 02525518 Manufacturer: Laboratoire Riva Inc.; listing date 2024-10-31 Health Canada: Marketed since 2026-02-26 · brand RIVA APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Laboratoire riva inc. · schedule Prescription

Check this DIN again · Health Canada product record

Riva-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101451 · Verify on the e-Formulary ↗ (DIN 02525518)

Source record

DIN 02525518: Riva-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id RIA Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525518 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101451

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525518

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Apixaban SDZ · DIN 02489228 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Apixaban SDZ · DIN 02489228 Manufacturer: Sandoz Canada Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-22 · brand SANDOZ APIXABAN SDZ · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Apixaban SDZ: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97930 · Verify on the e-Formulary ↗ (DIN 02489228)

Source record

DIN 02489228: Sandoz Apixaban SDZ Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489228 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97930

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: resolved shortage (ended 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489228

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Apixaban Tablet · DIN 02487519 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Apixaban Tablet · DIN 02487519 Manufacturer: Sandoz Canada Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-11 · brand SANDOZ APIXABAN TABLET · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Apixaban Tablet: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97767 · Verify on the e-Formulary ↗ (DIN 02487519)

Source record

DIN 02487519: Sandoz Apixaban Tablet Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487519 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97767

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487519

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Apixaban · DIN 02510464 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Taro-Apixaban · DIN 02510464 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-21 · brand TARO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Sun pharma canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Taro-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99968 · Verify on the e-Formulary ↗ (DIN 02510464)

Source record

DIN 02510464: Taro-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id TAR Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510464 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99968

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Teva-Apixaban · DIN 02484994 · $0.4084

Shortage status: resolved shortage (ended 2025-04-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510464

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Apixaban · DIN 02484994 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Apixaban · DIN 02484994 Manufacturer: Teva Canada Limited; listing date 2024-01-31 Health Canada: Marketed since 2023-09-22 · brand TEVA-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 2.5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97524 · Verify on the e-Formulary ↗ (DIN 02484994)

Source record

DIN 02484994: Teva-Apixaban Raw flags: sec3=Y Item: 201200089; group id 251; item number 0443; lccId None; manufacturer id TEV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484994 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97524

Interchangeable products

Ach-Apixaban · DIN 02487713 · $0.4084 Apixaban · DIN 02530708 · $0.4084 Apixaban · DIN 02548879 · $0.4084 Apo-Apixaban · DIN 02487381 · $0.4084 Auro-Apixaban · DIN 02486806 · $0.4084 Bio-Apixaban · DIN 02527979 · $0.4084 Eliquis · DIN 02377233 · $0.4084 Jamp Apixaban · DIN 02528924 · $0.4084 M-Apixaban · DIN 02529009 · $0.4084 Mar-Apixaban · DIN 02492369 · $0.4084 Mint-Apixaban · DIN 02495430 · $0.4084 NRA-Apixaban · DIN 02526050 · $0.4084 NRA-Apixaban Tablets · DIN 02546884 · $0.4084 Nat-Apixaban · DIN 02492814 · $0.4084 Riva-Apixaban · DIN 02525518 · $0.4084 Sandoz Apixaban SDZ · DIN 02489228 · $0.4084 Sandoz Apixaban Tablet · DIN 02487519 · $0.4084 Taro-Apixaban · DIN 02510464 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02484994

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Apixaban · DIN 02487721 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Apixaban · DIN 02487721 Manufacturer: Accord Healthcare Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-27 · brand ACH-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 5 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97787 · Verify on the e-Formulary ↗ (DIN 02487721)

Source record

DIN 02487721: Ach-Apixaban Raw flags: sec3=Y Item: 201200090; group id 251; item number 0444; lccId None; manufacturer id ACH Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487721 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97787

Interchangeable products

Apixaban · DIN 02530716 · $0.4084 Apixaban · DIN 02548887 · $0.4084 Apo-Apixaban · DIN 02487403 · $0.4084 Auro-Apixaban · DIN 02486814 · $0.4084 Bio-Apixaban · DIN 02527987 · $0.4084 Eliquis · DIN 02397714 · $0.4084 Jamp Apixaban · DIN 02528932 · $0.4084 M-Apixaban · DIN 02529017 · $0.4084 Mar-Apixaban · DIN 02492377 · $0.4084 Mint-Apixaban · DIN 02495449 · $0.4084 NRA-Apixaban · DIN 02526069 · $0.4084 NRA-Apixaban Tablets · DIN 02546892 · $0.4084 Nat-Apixaban · DIN 02492822 · $0.4084 Riva-Apixaban · DIN 02525526 · $0.4084 Sandoz Apixaban SDZ · DIN 02489236 · $0.4084 Sandoz Apixaban Tablet · DIN 02487527 · $0.4084 Taro-Apixaban · DIN 02510472 · $0.4084 Teva-Apixaban · DIN 02485001 · $0.4084

Shortage status: resolved shortage (ended 2025-11-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487721

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apixaban · DIN 02530716 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apixaban · DIN 02530716 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-12-21 Health Canada: Marketed since 2026-08-07 · brand APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101987 · Verify on the e-Formulary ↗ (DIN 02530716)

Source record

DIN 02530716: Apixaban Raw flags: sec3=Y Item: 201200090; group id 251; item number 0444; lccId None; manufacturer id SIV Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530716 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101987

Interchangeable products

Ach-Apixaban · DIN 02487721 · $0.4084 Apixaban · DIN 02548887 · $0.4084 Apo-Apixaban · DIN 02487403 · $0.4084 Auro-Apixaban · DIN 02486814 · $0.4084 Bio-Apixaban · DIN 02527987 · $0.4084 Eliquis · DIN 02397714 · $0.4084 Jamp Apixaban · DIN 02528932 · $0.4084 M-Apixaban · DIN 02529017 · $0.4084 Mar-Apixaban · DIN 02492377 · $0.4084 Mint-Apixaban · DIN 02495449 · $0.4084 NRA-Apixaban · DIN 02526069 · $0.4084 NRA-Apixaban Tablets · DIN 02546892 · $0.4084 Nat-Apixaban · DIN 02492822 · $0.4084 Riva-Apixaban · DIN 02525526 · $0.4084 Sandoz Apixaban SDZ · DIN 02489236 · $0.4084 Sandoz Apixaban Tablet · DIN 02487527 · $0.4084 Taro-Apixaban · DIN 02510472 · $0.4084 Teva-Apixaban · DIN 02485001 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02530716

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apixaban · DIN 02548887 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apixaban · DIN 02548887 Manufacturer: Sanis Health Inc.; listing date 2024-12-30 Health Canada: Marketed since 2024-11-06 · brand APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103771 · Verify on the e-Formulary ↗ (DIN 02548887)

Source record

DIN 02548887: Apixaban Raw flags: sec3=Y Item: 201200090; group id 251; item number 0444; lccId None; manufacturer id SAI Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548887 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103771

Interchangeable products

Ach-Apixaban · DIN 02487721 · $0.4084 Apixaban · DIN 02530716 · $0.4084 Apo-Apixaban · DIN 02487403 · $0.4084 Auro-Apixaban · DIN 02486814 · $0.4084 Bio-Apixaban · DIN 02527987 · $0.4084 Eliquis · DIN 02397714 · $0.4084 Jamp Apixaban · DIN 02528932 · $0.4084 M-Apixaban · DIN 02529017 · $0.4084 Mar-Apixaban · DIN 02492377 · $0.4084 Mint-Apixaban · DIN 02495449 · $0.4084 NRA-Apixaban · DIN 02526069 · $0.4084 NRA-Apixaban Tablets · DIN 02546892 · $0.4084 Nat-Apixaban · DIN 02492822 · $0.4084 Riva-Apixaban · DIN 02525526 · $0.4084 Sandoz Apixaban SDZ · DIN 02489236 · $0.4084 Sandoz Apixaban Tablet · DIN 02487527 · $0.4084 Taro-Apixaban · DIN 02510472 · $0.4084 Teva-Apixaban · DIN 02485001 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02548887

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Apixaban · DIN 02487403 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Apixaban · DIN 02487403 Manufacturer: Apotex Inc.; listing date 2022-08-31 Health Canada: Marketed since 2022-06-20 · brand APO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97757 · Verify on the e-Formulary ↗ (DIN 02487403)

Source record

DIN 02487403: Apo-Apixaban Raw flags: sec3=Y Item: 201200090; group id 251; item number 0444; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487403 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97757

Interchangeable products

Ach-Apixaban · DIN 02487721 · $0.4084 Apixaban · DIN 02530716 · $0.4084 Apixaban · DIN 02548887 · $0.4084 Auro-Apixaban · DIN 02486814 · $0.4084 Bio-Apixaban · DIN 02527987 · $0.4084 Eliquis · DIN 02397714 · $0.4084 Jamp Apixaban · DIN 02528932 · $0.4084 M-Apixaban · DIN 02529017 · $0.4084 Mar-Apixaban · DIN 02492377 · $0.4084 Mint-Apixaban · DIN 02495449 · $0.4084 NRA-Apixaban · DIN 02526069 · $0.4084 NRA-Apixaban Tablets · DIN 02546892 · $0.4084 Nat-Apixaban · DIN 02492822 · $0.4084 Riva-Apixaban · DIN 02525526 · $0.4084 Sandoz Apixaban SDZ · DIN 02489236 · $0.4084 Sandoz Apixaban Tablet · DIN 02487527 · $0.4084 Taro-Apixaban · DIN 02510472 · $0.4084 Teva-Apixaban · DIN 02485001 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487403

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Apixaban · DIN 02486814 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Apixaban · DIN 02486814 Manufacturer: Auro Pharma Inc.; listing date 2023-01-31 Health Canada: Marketed since 2022-11-28 · brand AURO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 5 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97698 · Verify on the e-Formulary ↗ (DIN 02486814)

Source record

DIN 02486814: Auro-Apixaban Raw flags: sec3=Y Item: 201200090; group id 251; item number 0444; lccId None; manufacturer id AUR Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02486814 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97698

Interchangeable products

Ach-Apixaban · DIN 02487721 · $0.4084 Apixaban · DIN 02530716 · $0.4084 Apixaban · DIN 02548887 · $0.4084 Apo-Apixaban · DIN 02487403 · $0.4084 Bio-Apixaban · DIN 02527987 · $0.4084 Eliquis · DIN 02397714 · $0.4084 Jamp Apixaban · DIN 02528932 · $0.4084 M-Apixaban · DIN 02529017 · $0.4084 Mar-Apixaban · DIN 02492377 · $0.4084 Mint-Apixaban · DIN 02495449 · $0.4084 NRA-Apixaban · DIN 02526069 · $0.4084 NRA-Apixaban Tablets · DIN 02546892 · $0.4084 Nat-Apixaban · DIN 02492822 · $0.4084 Riva-Apixaban · DIN 02525526 · $0.4084 Sandoz Apixaban SDZ · DIN 02489236 · $0.4084 Sandoz Apixaban Tablet · DIN 02487527 · $0.4084 Taro-Apixaban · DIN 02510472 · $0.4084 Teva-Apixaban · DIN 02485001 · $0.4084

Shortage status: resolved shortage (ended 2025-01-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486814

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Apixaban · DIN 02527987 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Bio-Apixaban · DIN 02527987 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2022-09-21 · brand BIO-APIXABAN · ATC B01AF02 APIXABAN · form Tablet · route Oral · ingredients APIXABAN 5 MG · company Biomed pharma · schedule Prescription

Check this DIN again · Health Canada product record

Bio-Apixaban: Formulary list price $0.4084/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4084 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101725 · Verify on the e-Formulary ↗ (DIN 02527987)

Source record

DIN 02527987: Bio-Apixaban Raw flags: sec3=Y Item: 201200090; group id 251; item number 0444; lccId None; manufacturer id BMP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.4084; ministry $0.4084 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527987 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101725

Interchangeable products

Ach-Apixaban · DIN 02487721 · $0.4084 Apixaban · DIN 02530716 · $0.4084 Apixaban · DIN 02548887 · $0.4084 Apo-Apixaban · DIN 02487403 · $0.4084 Auro-Apixaban · DIN 02486814 · $0.4084 Eliquis · DIN 02397714 · $0.4084 Jamp Apixaban · DIN 02528932 · $0.4084 M-Apixaban · DIN 02529017 · $0.4084 Mar-Apixaban · DIN 02492377 · $0.4084 Mint-Apixaban · DIN 02495449 · $0.4084 NRA-Apixaban · DIN 02526069 · $0.4084 NRA-Apixaban Tablets · DIN 02546892 · $0.4084 Nat-Apixaban · DIN 02492822 · $0.4084 Riva-Apixaban · DIN 02525526 · $0.4084 Sandoz Apixaban SDZ · DIN 02489236 · $0.4084 Sandoz Apixaban Tablet · DIN 02487527 · $0.4084 Taro-Apixaban · DIN 02510472 · $0.4084 Teva-Apixaban · DIN 02485001 · $0.4084

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527987

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Look up one drug

APIXABAN

Ach-Apixaban · DIN 02487713 · 2.5mg · tablet

Apixaban · DIN 02530708 · 2.5mg · tablet

Apixaban · DIN 02548879 · 2.5mg · tablet

Apo-Apixaban · DIN 02487381 · 2.5mg · tablet

Auro-Apixaban · DIN 02486806 · 2.5mg · tablet

Bio-Apixaban · DIN 02527979 · 2.5mg · tablet

Eliquis · DIN 02377233 · 2.5mg · tablet

Jamp Apixaban · DIN 02528924 · 2.5mg · tablet

M-Apixaban · DIN 02529009 · 2.5mg · tablet

Mar-Apixaban · DIN 02492369 · 2.5mg · tablet

Mint-Apixaban · DIN 02495430 · 2.5mg · tablet

NRA-Apixaban Tablets · DIN 02546884 · 2.5mg · tablet

Nat-Apixaban · DIN 02492814 · 2.5mg · tablet

Riva-Apixaban · DIN 02525518 · 2.5mg · tablet

Sandoz Apixaban SDZ · DIN 02489228 · 2.5mg · tablet

Sandoz Apixaban Tablet · DIN 02487519 · 2.5mg · tablet

Taro-Apixaban · DIN 02510464 · 2.5mg · tablet

Teva-Apixaban · DIN 02484994 · 2.5mg · tablet

Ach-Apixaban · DIN 02487721 · 5mg · tablet

Apixaban · DIN 02530716 · 5mg · tablet

Apixaban · DIN 02548887 · 5mg · tablet

Apo-Apixaban · DIN 02487403 · 5mg · tablet

Auro-Apixaban · DIN 02486814 · 5mg · tablet

Bio-Apixaban · DIN 02527987 · 5mg · tablet

Matched class: 20:12 Coagulants and Anti-Coagulants

RIVAROXABAN

DABIGATRAN ETEXILATE

ENOXAPARIN

WARFARIN

DALTEPARIN SODIUM

FONDAPARINUX SODIUM

NADROPARIN CALCIUM

TICAGRELOR

TINZAPARIN SODIUM

EPTIFIBATIDE

EDOXABAN

TRANEXAMIC ACID

Availability